Skip to main content

Pemitinib 13.5 mg ( Pemigatinib)

Introduction

Pemitinib.com provides educational information about Pemitinib 13.5 mg, identified on this website as a product containing pemigatinib.

Medical information about prescription anticancer medicines should be based on reliable scientific, clinical and regulatory documentation.

This page identifies the principal types of authoritative information used to prepare educational content about pemigatinib. It also explains the purpose of each source and the importance of distinguishing reference-product information from product-specific information about Pemitinib.

The information presented on this website is intended for general education. It is not a replacement for the complete official prescribing information or professional medical advice.

1. U.S. Food and Drug Administration

The U.S. Food and Drug Administration (FDA) is a regulatory authority responsible for evaluating and overseeing medicines in the United States.

FDA prescribing information is an important source for understanding approved indications, dosage schedules, warnings, precautions, adverse reactions and drug interactions.

The U.S. reference-product information for PEMAZYRE provides details about pemigatinib, including:

  • FGFR2-altered cholangiocarcinoma indication.
  • FGFR1-rearranged myeloid/lymphoid neoplasm indication.
  • Recommended dosage and administration.
  • Dose modifications.
  • Hyperphosphatemia.
  • Ocular toxicity.
  • Embryo-fetal toxicity.
  • Adverse reactions.
  • Drug interactions.

Regulatory information should always be interpreted in the context of the country and product to which it applies.

2. DailyMed Prescribing Information

DailyMed provides official labeling information submitted to the U.S. National Library of Medicine.

The PEMAZYRE prescribing information is an important source for understanding the established U.S. reference product containing pemigatinib.

It describes the medicine’s active ingredient, indications, dosage, administration instructions, warnings, adverse reactions and clinical pharmacology.

The labeling also provides information about dose adjustments, missed doses and important safety monitoring.

The version applicable at the time of prescribing should be consulted because product labeling can change.

3. European Medicines Agency

The European Medicines Agency (EMA) provides regulatory information about medicines authorized in the European Union.

Its public information about PEMAZYRE includes the European indication for selected adults with locally advanced or metastatic FGFR2 fusion or rearrangement-positive cholangiocarcinoma that has progressed after at least one previous systemic therapy.

The European product information also describes dosage, safety considerations and product characteristics.

European regulatory indications should not automatically be applied to patients in other jurisdictions.

4. Official Product Information for PEMAZYRE

The established reference brand PEMAZYRE contains pemigatinib.

Its official product information provides details about the medicine’s formulation, strengths, administration and safety requirements.

The reference product is available in 4.5 mg, 9 mg and 13.5 mg tablet strengths.

This information helps explain pemigatinib as an active pharmaceutical ingredient and provides a reference for its recognized clinical use.

However, it does not establish the manufacturer, packaging, authorization or quality status of a separately branded Pemitinib product.

5. Incyte Pharmaceutical Development Information

Incyte is associated with the development of pemigatinib and the reference product PEMAZYRE.

Company information about the development of pemigatinib provides background on the medicine’s discovery and development as a targeted FGFR inhibitor.

This information helps explain the scientific and pharmaceutical background of the active ingredient.

It should not be used to identify Incyte as the manufacturer of Pemitinib unless specific product documentation establishes that relationship.

6. Clinical Research on Pemigatinib

Clinical research provides information about how a medicine performs in selected patient populations.

Studies of pemigatinib have examined its use in patients with molecularly defined cancers involving FGFR abnormalities.

Relevant research areas include:

  • FGFR2-altered cholangiocarcinoma.
  • FGFR1-rearranged myeloid/lymphoid neoplasms.
  • Tumor response.
  • Duration of response.
  • Treatment tolerability.
  • Adverse reactions.
  • Dose modification.
  • Molecular testing and patient selection.

Clinical trial findings should be interpreted carefully because outcomes may depend on the study population, study design, previous treatments and other clinical factors.

Results from one indication should not automatically be generalized to another.

7. Molecular Diagnostic Information

Molecular diagnostic information is important for understanding the treatment eligibility requirements for pemigatinib.

FGFR2 fusions and qualifying rearrangements are relevant to the cholangiocarcinoma indication.

FGFR1 rearrangements are relevant to the U.S. indication for selected myeloid/lymphoid neoplasms.

Validated diagnostic testing helps identify these genetic abnormalities.

A qualified healthcare professional must interpret the molecular findings and determine whether the results meet the applicable prescribing requirements.

8. Pharmaceutical Safety Information

Safety information from regulatory labeling is essential when preparing educational content about pemigatinib.

Important safety topics include:

  • Hyperphosphatemia.
  • Retinal pigment epithelial detachment.
  • Other ocular adverse reactions.
  • Nail toxicity.
  • Diarrhea.
  • Fatigue.
  • Stomatitis.
  • Drug interactions.
  • Pregnancy-related risks.
  • Dose interruption and reduction.

Safety recommendations may change as additional evidence becomes available or regulatory authorities update product information.

9. Product-Specific Manufacturer Documentation

Manufacturer information should be established through documentation relating to the actual Pemitinib product.

Appropriate documentation may include:

  • Product packaging.
  • Official product leaflet.
  • Manufacturer’s declaration.
  • Pharmaceutical quality documentation.
  • Country-specific registration records.
  • Marketing authorization documentation.
  • Authorized distribution information.

Information about PEMAZYRE or its developer does not independently verify the manufacturer of Pemitinib.

10. Reference Information and Publication Standards

The educational material on Pemitinib.com is organized around established medical and pharmaceutical information.

The objective is to explain the medicine’s pharmacological characteristics, recognized uses, treatment schedules, adverse reactions and safety requirements without presenting unverified product details as confirmed facts.

Information that is specific to a product must be supported by that product’s own documentation.

Important Regulatory Distinction

A medicine’s regulatory approval is specific to its active ingredient, product, formulation, indication, manufacturer and jurisdiction.

For this reason, the U.S. indication for FGFR1-rearranged myeloid/lymphoid neoplasms should not automatically be described as an approved indication in every country.

Similarly, the approval of PEMAZYRE should not be interpreted as proof that Pemitinib has the same authorization.

Medical Information Disclaimer

References and regulatory information are provided to explain the medical background of pemigatinib.

Pemitinib.com does not guarantee that every product-specific detail has been independently verified or that all information reflects the latest regulatory position in every country.

Healthcare professionals and patients should consult the current official prescribing information applicable to the medicine they are using.

Conclusion

Reliable medical and regulatory information is essential for responsible communication about targeted anticancer medicines.

The principal reference sources for pemigatinib include FDA prescribing information, DailyMed, EMA product information, official reference-product documentation and relevant clinical research.

Product-specific details about Pemitinib must be confirmed independently through its own pharmaceutical and regulatory documentation.